Sensor Specialist Neuranics Secures £1.9m Investment Led by Par Equity

– Neuranics develops pioneering magnetic sensor technology for applications in the health and fitness, and metaverse sectors




GLASGOW, Scotland–(BUSINESS WIRE)–Sensor specialist startup Neuranics has secured a $2.3 million investment led by Par Equity. GU Holdings, the investment company for the University of Glasgow, Old College Capital, the University of Edinburgh’s venture investment fund, and London-based Creator Fund, who back scientific founding teams, also participated in the pre-seed round.

Founded in 2021 as a joint spinout from the University of Glasgow and the University of Edinburgh, Neuranics develops pioneering magnetic sensors integrated with semiconductor technology for health, fitness, and metaverse applications. Neuranics’s patented technology uses scalable spintronics sensors powered by semiconductors to detect tiny magnetic signals from organs in the body – for example the heart and muscles of the arms, which the company says could transform the current shortcomings of health monitoring devices and human-machine interfaces.

The company’s magnetocardiography (MCG) sensors are easier to use than traditional electrocardiography (ECG) sensors. In a human-machine interface application, the magnetomyography (MMG) sensing system can estimate single finger movements by detecting the magnetic activity of the forearm muscles. These sensors improve the latency issues when used to control a robotic hand, or interact with virtual objects in the metaverse.

Neuranics’s chip-scale sensors are low-cost, scalable, low-power, and operate at room temperature, as opposed to the current method of measuring magnetic signals which are characterised by large, complex, expensive, lab or clinic-based equipment.

CEO Noel McKenna said: “Our breakthrough technology will enable much better sensor resolution for human-machine interface, will have huge benefits for health and fitness devices, and also controllers in the metaverse. We see global demand for our technology, and we are already working with several Tier 1 consumer electronics groups. We want to be the world’s leading magnetic sensor company, selling our sensor chips or licensing our technology into hundreds of millions of products per annum.”

Robert Higginson, Partner, Par Equity said: “Rarely do we discover both a transformational technology and such a well-rounded team, with whom we can partner over the long-term to create a company capable of radically improving a broad range of use cases in a number of industry verticals. Neuranics’s patented technologies complement many other technologies developed by our portfolio companies and are a good example of Par Equity’s tough tech focus.”

To learn more about Neuranics, visit our website at http://neuranics.com/

Notes:

– The company was co-founded by chief technology officer (CTO) and Professor of Nanoelectronics at the University of Glasgow, Hadi Heidari, Lead Engineer Dr Siming Zuo, and University of Edinburgh Professor of Digital Health and Neuranics’s chief strategy officer (CSO), Kia Nazarpour.

Contacts

Nick Freer

[email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.